Episodic ataxia type 2: a previously undescribed variant in the CACNA1A gene
Objective: To describe a previously unreported variant in the CACNA1A gene in a patient with episodic ataxia type 2 (EA2) phenotype. Background: EA2 is the…Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson’s disease
Objective: To comprehensively characterize the blood-based DNA methylation alterations related to sex in patients with Parkinson's disease (PD), shedding light on the underlying genes and…An IMU- based Objective Quantification Method for Bradykinesia Evaluation in Parkinson’s disease
Objective: Proposing an inertial measurement unit (IMU)-based objective quantification method for bradykinesia evaluation in Parkinson’s disease (PD) using MDS UPDRS III. Background: MDS-UPDRS III rating…Technological Approach to Phenotypical Characterization of Functional Movement Disorders
Objective: To evaluate the reliability of technological devices for phenotype definition and rehabilitative treatment tailoring of patients affected by Functional Movement Disorders (FMDs) Background: FMDs…Non-tremor motor dysfunction in Parkinson’s disease is associated with decreased [18F]FMPEP-d2 binding
Objective: To explore the relationship between cannabinoid receptor type 1 (CB1) availability and motor symptoms in Parkinson’s disease (PD) with [18F]FMPEP-d2 positron emission tomography (PET).…Subthalamic nucleus deep brain stimulation in the beta range modulates cortical beta oscillations in Parkinson’s disease patients
Objective: To examine whether it is possible to modulate cortical beta oscillations with subthalamic nucleus (STN) deep brain stimulation (DBS) in the beta range. Background:…Is working memory training success in Parkinson’s disease determined by cortical thickness and white matter lesions?
Objective: We aimed to evaluate the influence of cortical thickness (CT) and white matter lesions (WML) on working memory training (WMT) success in cognitively unimpaired…Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials
Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…The use of contrast-enhanced ultrasonography of muscle spasticity and myofascial trigger points
Objective: The aim of this study was to evaluate the relevance of contrast-enhanced ultrasound (CEUS) for evaluating MTrPs vascularity and its potential added value for…Can radiofrequency lesion be better than DBS?
Objective: Pallidotomy represents a viable alternative for Parkinson disease(PD) symptoms treatment and has several important advantages, including a decreased need for access to specialists and clinical follow-up, improved affordability, and a lower infection risk, producing high long-term success rates and low morbidity rates. Background: Pallidotomy is recognized as effective for treating the symptoms of Parkinson's disease. Sometimes, radiofrequency may…
- « Previous Page
- 1
- …
- 150
- 151
- 152
- 153
- 154
- …
- 1374
- Next Page »